{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination can sensitize tumors that are otherwise non-responsive to immune checkpoint blockade (ICI) therapy.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade",
          "line_ref": "L4"
        },
        {
          "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        }
      ],
      "caveat": "The human data supporting this claim is from a retrospective, non-randomized cohort, meaning the correlation is highly susceptible to residual confounding factors."
    },
    {
      "claim_id": "C02",
      "claim": "The sensitization mechanism is dependent on the induction of local type I interferon signaling within the tumor microenvironment.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        },
        {
          "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        }
      ],
      "caveat": "While confirmed by blockade in mice, the relative strength and duration of the interferon response in human tumors is still unknown."
    },
    {
      "claim_id": "C03",
      "claim": "mRNA vaccination significantly broadens the tumor's antigen presentation profile by increasing the fraction of proteins represented in the MHC-I peptidome.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape",
          "line_ref": "L29"
        },
        {
          "quote": "A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.",
          "line_ref": "L44"
        }
      ],
      "caveat": "This claim is based on immunopeptidomics data from preclinical models; equivalent effects in human tumors require further validation."
    },
    {
      "claim_id": "C04",
      "claim": "The study provides sufficient biological rationale to move to prospective clinical trials, but no immediate changes to standard clinical protocols are justified.",
      "strength": "tentative",
      "evidence": [
        {
          "quote": "The study supports a biologically coherent hypothesis that intratumoral mRNA vaccination can prime tumors for stronger ICI responses",
          "line_ref": "L56"
        },
        {
          "quote": "but prospective randomized studies are required before clinical protocol changes are justified.",
          "line_ref": "L56"
        }
      ],
      "caveat": "The retrospective human data, despite the statistically significant p-value, cannot rule out the influence of unmeasured confounding variables."
    }
  ]
}